OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424

/PRNewswire/ -- OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the first patients have been enrolled in both of the Phase 2 studies...

Related Keywords

Taiwan ,Taipei ,T Ai Pei ,United States ,Adagloxad Simolenin ,Michael Chang ,Kevin Poulos ,Futures Bureau ,Pharma Inc ,Pharma United States Inc ,Cohort Expansion Study Evaluating ,Therapeutic Activity ,Advanced Solid ,Chief Executive Officer ,Antibody Drug Conjugate ,Asia Pacific ,Globo Series ,Private Securities Litigation Reform Act ,Taiwan Securities ,Obi Pharma ,Nc ,